280 related articles for article (PubMed ID: 24053128)
21. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies.
Pal RP; Elmussareh M; Chanawani M; Khan MA
BJU Int; 2012 Feb; 109(3):367-71. PubMed ID: 21883818
[TBL] [Abstract][Full Text] [Related]
22. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
[TBL] [Abstract][Full Text] [Related]
23. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
26. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
[TBL] [Abstract][Full Text] [Related]
29. Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau).
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Kluth LA; Wyler SF; Recker F; Kwiatkowski M
Int J Cancer; 2015 Aug; 137(3):553-9. PubMed ID: 25565393
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
[TBL] [Abstract][Full Text] [Related]
31. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
32. No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Bill-Axelson A; Holmberg L; Norlén B; Busch C; Norberg M
J Urol; 2003 Oct; 170(4 Pt 1):1180-3. PubMed ID: 14501720
[TBL] [Abstract][Full Text] [Related]
33. Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period.
Kawa SM; Stroomberg HV; Larsen SB; Helgstrand JT; Toft BG; Brasso K; Røder MA
Urology; 2021 Sep; 155():20-25. PubMed ID: 34171348
[TBL] [Abstract][Full Text] [Related]
34. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL).
Lu CH; Lin TP; Shen SH; Huang YH; Chung HJ; Kuo JY; Huang WJS; Wu HHH; Chang YH; Lin ATL; Chen KK
J Chin Med Assoc; 2017 Jul; 80(7):413-418. PubMed ID: 28529023
[TBL] [Abstract][Full Text] [Related]
36. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
[TBL] [Abstract][Full Text] [Related]
37. The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis.
Klemann N; Røder MA; Helgstrand JT; Brasso K; Toft BG; Vainer B; Iversen P
Scand J Urol; 2018 Jun; 52(3):169-173. PubMed ID: 29514539
[TBL] [Abstract][Full Text] [Related]
38. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.
Lavallée LT; Binette A; Witiuk K; Cnossen S; Mallick R; Fergusson DA; Momoli F; Morash C; Cagiannos I; Breau RH
Mayo Clin Proc; 2016 Jan; 91(1):17-22. PubMed ID: 26688045
[TBL] [Abstract][Full Text] [Related]
39. Mass screening of prostate cancer in Changchun City of China.
Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales.
Smith DP; Armstrong BK
Med J Aust; 1998 Jul; 169(1):17-20. PubMed ID: 9695696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]